title: High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer.
abstract: An enhanced antineoplastic effect of 5-fluorouracil in patients with advanced colorectal cancer has been produced either by combination with folinic acid or administration by continuous infusion. Thirty-seven patients with advanced measurable colorectal cancer received high-dose folinic acid (LV 200 mg/m2) followed by 5-fluorouracil i.v. bolus (300 mg/m2) and continuous infusion (300 mg/m2) on days 1 and 2 then 14 and 15 every 4 weeks. In the absence of toxicity, 5-FU was increased to 400 mg/m2 i.v. bolus and continuous infusion at course 2 and to 500 mg/m2 at course 3 and from course 4 maintained at 500 mg/m2. Responses were: complete responses: 1 (2.7%), partial responses: 19 (51.4%), no change: 8 (21.6%) and progressive disease: 9 (24.3%). CEA decrease was correlated with response. Median duration of response was 11 months. Median survival was 18 months, 21% of the patients were alive at 2 years. Toxicity was low, with diarrhea in 17% and nausea in 11.5% of the patients. LV-5-FU bolus and continuous infusion is safe and has definite activity in metastatic colorectal cancer.
authors.affiliation: Hôpital Saint-Antoine, Paris, France.
authors.forename: A
authors.initials: A
authors.lastname: De Gramont
authors.forename: M
authors.initials: M
authors.lastname: Krulik
authors.forename: J
authors.initials: J
authors.lastname: Cady
authors.forename: B
authors.initials: B
authors.lastname: Lagadec
authors.forename: J E
authors.initials: JE
authors.lastname: Maisani
authors.forename: J P
authors.initials: JP
authors.lastname: Loiseau
authors.forename: J D
authors.initials: JD
authors.lastname: Grange
authors.forename: G
authors.initials: G
authors.lastname: Gonzalez-Canali
authors.forename: B
authors.initials: B
authors.lastname: Demuynck
authors.forename: C
authors.initials: C
authors.lastname: Louvet
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002272:Carcinoembryonic Antigen / Q000378:metabolism; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies
chemical_list: D002272:Carcinoembryonic Antigen; D002955:Leucovorin; D005472:Fluorouracil